Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor,…
Telecom Review Leaders’ Summit: The world’s first 5G-A region sets sail for the Mobile AI Era
DUBAI, United Arab Emirates, Dec. 14, 2024 /PRNewswire/ -- The panel at…
